Investment Column: Overseas push is a winner for Mothercare

Britvic; GW Pharmaceuticals


Our view: Buy

Share price: 423p (+7p)

The conventional wisdom is that parents are never likely to stop spending money on their children, even in a recession.

Yesterday's final results from the children's goods retailer Mothercare underlined that argument, even if the company would claim that it is being proactive in ensuring it more than survives the downturn. A push for more internet sales and opening more stores abroad contributed to a 12.4 per cent increase in full-year pre-tax profits and, more importantly for investors, a 20.8 per cent jump in the dividend.

The future, says its chief executive Ben Gordon, is more overseas stores, especially in China, knocking down rental costs in the UK, and maintaining internet sales growth, which is up 25 per cent in the past year.

Clearly there is much to shout about and investors would be crazy not to consider the shares. Mr Gordon says the stock has outperformed the market in the past year, but we are disappointed the shares were up just 3 per cent in the past quarter, before yesterday's results. The stock trades at a discount, which is good news for those looking for a bargain, but we would also worry about the market not fully getting the story.

Maybe it is the pressure on margins as a result of sterling's weakness against the dollar (the group sources much of its stock in East Asia) that has made some investors more nervous about the stock in recent weeks.

Whatever the reason, we would argue that yesterday's numbers more than compensate for any residual concerns about the group and think that, at its current level, the share price is at an attractive entry point. Buy.

Britvic

Our view: Buy

Share price: 303p (+34.25p)

Those looking for a solid investment, a strong dividend and the potential for share price growth, look no further than Britvic, the FTSE 250-listed soft drinks company that makes Tango and Robinsons squash, and which has the licence to sell Pepsi in the UK.

At first glance, there cannot be a more compelling investment case: the group posted a better than expected 16.3 per cent increase in half-year pre-tax profits yesterday and its chief executive, Paul Moody, says there is a recovery under way in the soft drinks market. Despite a 12.7 per cent rise in the share price yesterday, the stock is still undervalued.

It is true that the shares have not performed as well as others during the recovery of recent weeks, but you cannot really argue with the facts. Mr Moody says he is comfortable with the £75m full-year profits consensus view of the analysts, arguing the better health in the sector will last.

UBS's watchers argue the shares are a buy, especially given the stock's recent lack of traction. "Year to date, Britvic has outperformed the market by 7 per cent, but underperformed the beverages sector by 9 per cent. Britvic trades on 9.9 times 2009 price- earnings, a 22 per cent discount to the sector, and offers a 12 per cent free cashflow yield," notes UBS. A solid buy then, especially with a dividend increase.

Perhaps the only fly in the ointment is that the UBS experts have a 12-month price target of just 280p. We think they will have to revise that soon, however, and would be at the front of the queue to buy the shares. Buy.

GW Pharmaceuticals

Our view: Buy

Share price: 82.75p (+3.75p)

As of yesterday, GW Pharmaceuticals joined a select band of biotech companies. The group posted its maiden profit as part of its interim results, which also confirmed the news of a few weeks ago that Sativex, its cannabis-based multiple sclerosis treatment, had passed all-important final phase drug trials. GW has submitted the data for approval in the EU, with the pharma giant Bayer licensed to market the drug.

The shares are up 122 per cent in the last three months alone and while some may be concerned that the stock might run out of steam, we would argue that it will inevitably strengthen as sales of Sativex grow, and as it meets requirements to treat other conditions, such as the pain caused by cancer. The analysts at KBC Peel Hunt agree: "We continue to see further upside in the coming months as Sativex is prepared for commercial launch and is eventually approved by the main European regulators, [we] keep our 120p price target. With an additional £10m milestone to come from Bayer for UK approval, GW's cash balance remains strong."

Hindsight is a wonderful thing, and of course investors would have been better buying the shares three months ago. We would argue, however, that they are still worth buying. Buy.

Start your day with The Independent, sign up for daily news emails
News
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Guru Careers: Communications Exec / PR Exec

£25 - £30K: Guru Careers: We are seeking a highly-motivated and ambitious Comm...

Guru Careers: Pricing Analyst

£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...

Day In a Page

On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific
In this the person to restore our trust in the banks?

In this the person to restore our trust in the banks?

Dame Colette Bowe - interview
When do the creative juices dry up?

When do the creative juices dry up?

David Lodge thinks he knows
The 'Cher moment' happening across fashion just now

Fashion's Cher moment

Ageing beauty will always be more classy than all that booty
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination

Health fears over school cancer jab

Shock new Freedom of Information figures show how thousands of girls have suffered serious symptoms after routine HPV injection
Fifa President Sepp Blatter warns his opponents: 'I forgive everyone, but I don't forget'

'I forgive everyone, but I don't forget'

Fifa president Sepp Blatter issues defiant warning to opponents
Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report

Weather warning

Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report
LSD: Speaking to volunteer users of the drug as trials get underway to see if it cures depression and addiction

High hopes for LSD

Meet the volunteer users helping to see if it cures depression and addiction
German soldier who died fighting for UK in Battle of Waterloo should be removed from museum display and given dignified funeral, say historians

Saving Private Brandt

A Belgian museum's display of the skeleton of a soldier killed at Waterloo prompts calls for him to be given a dignified funeral